Sherwin Yen, MD
Endocrinology, Diabetes & Metabolism · Austin, TXNPI 1720212426
Payments from drug & device makers
Across 258 payments — averaging $30.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$2K
- Novo Nordisk$1K
- Tandem Diabetes Care, Inc.$891
- Amgen$543
- Abbott$518
- Lilly USA, LLC$471
- plus $2K from 30 others
What the payments were for
- Speaking & faculty fees$1,82023%
- Travel & lodging$78310%
- Food & beverage$5,26566%
- Education$681%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corcept Therapeutics | 6 | $2,015 |
| Novo Nordisk | 71 | $1,145 |
| Tandem Diabetes Care, Inc. | 8 | $891 |
| Amgen(2 entities) | 26 | $543 |
| Abbott | 27 | $518 |
| Lilly USA, LLC | 26 | $471 |
| Dexcom, Inc. | 12 | $297 |
| Sanofi-aventis U.S. LLC | 7 | $278 |
| BETA Bionics, Inc. | 7 | $216 |
| Boehringer Ingelheim | 6 | $149 |
| Medtronic | 7 | $141 |
| Bayer | 2 | $141 |
| Insulet Corporation | 7 | $129 |
| Rhythm Pharmaceuticals, Inc. | 4 | $116 |
| Cequr Corporation | 2 | $108 |
| AbbVie | 5 | $96 |
| Amneal Pharmaceuticals LLC | 3 | $79 |
| Xeris Pharmaceuticals, Inc. | 4 | $75 |
| Mannkind Corporation | 2 | $74 |
| Radius Health, Inc. | 3 | $70 |
| AstraZeneca(2 entities) | 3 | $51 |
| Sequel Med Tech, LLC | 2 | $51 |
| Kyowa Kirin, Inc. | 2 | $48 |
| Novartis | 2 | $45 |
| BD | 2 | $33 |
| IBSA Pharma Inc. | 2 | $27 |
| Ascendis Pharma Endocrinology Inc | 1 | $25 |
| Recordati_rare_diseases_inc. | 1 | $23 |
| Ascensia Diabetes Care US Inc. | 1 | $21 |
| Acella Pharmaceuticals, LLC | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $19 |
| Valeritas, Inc. | 1 | $18 |
| Lifescan, Inc. | 1 | $17 |
| Sandoz | 1 | $17 |
| Antares Pharma, Inc. | 1 | $16 |
| Vistapharm, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$1,945
- t-slim insulin pump$703
- TZIELD$149
- Kerendia$122
How this compares
$7,997 in reported general payments places this provider in the 60th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 355 | $562,316 |
| MounjaroTirzepatide | 286 | $406,268 |
| FarxigaDapagliflozin Propanediol | 131 | $171,261 |
| TrulicityDulaglutide | 101 | $164,095 |
| JardianceEmpagliflozin | 101 | $143,602 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 84 | $82,725 |
| RybelsusSemaglutide | 51 | $81,591 |
| Tresiba Flextouch U-100Insulin Degludec | 79 | $72,674 |
| Xigduo XrDapaglifloz Propaned/Metformin | 52 | $64,539 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 37 | $59,139 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 30 | $47,471 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 39 | $47,454 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 13 | $43,415 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 46 | $41,133 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 22 | $40,583 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Tresiba | $1,145 | $650,223423 claims |
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog | $471 | $593,235419 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Trijardy Xr | $149 | $233,512161 claims |
| AstraZenecaFarxiga | $51 | $171,261131 claims |
| AbbVieSynthroid | $96 | $12,920145 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $79 | $7,881671 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Austin
- Thomas BlevinsAustin$7.4M
- Luis CasaubonAustin$3.5M
- Lindsay HarrisonAustin$2.2M
- Jean ChenAustin$1.8M
- Tira Chaicha-BromAustin$1.7M
- Valerie EspinosaAustin$1.2M
- Julio RosenstockDallas$24.9M
- Michelle WelchShavano Park$17.3M
- Maria CabanillasHouston$16.4M
- Sumana GangiMesquite$13.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.